Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Multicentric Phase III [study] Evaluating the Benefit of a Sequential Regimen Associating FEC 100 [fluorouracil + epirubicin + cyclophosphamide] and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients

Next Previous
Search
Trial Profile

A Randomized, Open Label, Multicentric Phase III [study] Evaluating the Benefit of a Sequential Regimen Associating FEC 100 [fluorouracil + epirubicin + cyclophosphamide] and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Ixabepilone (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TavIx

    • Most Recent Events

    • 26 Sep 2018 Five-year efficacy results published in the European Journal of Cancer.
    • 03 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top